| Date | Time | Source | Headline | Symbol | Company |
| 09/27/2017 | 6:30AM | Business Wire | Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Ma... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/13/2017 | 6:08PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/13/2017 | 5:53PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/13/2017 | 8:47AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/13/2017 | 7:30AM | Business Wire | Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/30/2017 | 4:00PM | Business Wire | Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/09/2017 | 4:10PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/07/2017 | 4:16PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/07/2017 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/03/2017 | 3:39PM | Business Wire | Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/28/2017 | 11:05AM | Business Wire | Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the T... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/28/2017 | 11:03AM | PR Newswire (US) | European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/28/2017 | 10:57AM | PR Newswire (US) | European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/25/2017 | 4:00PM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third ... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/26/2017 | 7:30AM | Business Wire | Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX Internati... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/23/2017 | 8:47AM | PR Newswire (US) | AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in A... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/23/2017 | 7:44AM | Business Wire | Enanta Announces that AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Ch... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/23/2017 | 7:36AM | PR Newswire (US) | AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in A... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/10/2017 | 4:05PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/09/2017 | 4:08PM | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/09/2017 | 4:01PM | Business Wire | CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/08/2017 | 4:03PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/08/2017 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/21/2017 | 6:19AM | Business Wire | Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Gleca... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/21/2017 | 1:00AM | PR Newswire (US) | Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/20/2017 | 7:40AM | Business Wire | Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigation... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/20/2017 | 7:30AM | PR Newswire (US) | AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12)... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/19/2017 | 6:28AM | Business Wire | Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) & Primary Biliary C... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/18/2017 | 4:00PM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Qu... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/14/2017 | 4:16PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |